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licenses/by-nc-nd/4.0/).these patients. The delegates discussed potential therapies,
from neoadjuvant treatment to combinations or sequentialcases in 2012 (>500,000 worldwide), with a prevalence of1. Introduction
Strategies to improve cancer care in the field of urothelial
carcinoma (UC) in the elderly or in patients unfit to receive
cisplatin treatment are urgently needed. This effort requires
multidisciplinary collaboration to provide the best care for
these patients.
An international multidisciplinary summit was held in
Geneva on April 11th 2015 to discuss unmet medical needs in
urothelial cancer. Key topics covered in the meeting included
defining difficult-to-treat UC patients and the challenges
encountered with both surgical and systemic treatment inisciplinary summit, Gene
7; fax: þ1 617 632 2165.
arvard.edu (J. Bellmunt).
his is an open access artregimens, maintenance therapy up to second-line manage-
ment, and future treatment opportunities that could improve
on current patient outcomes. Molecular specificities and
future perspectives of UCwere also discussed. Each individual
topic of the meeting is outlined in the chapters below.2. Defining ‘difficult-to-treat patients’ with UC
Maria De Santis, United Kingdom
2.1. Bladder cancer is a disease of the elderly
In the EuropeanUnion, therewere 118,365 new bladder cancer
389,287 cases, and 39,522 deaths. Bladder cancer incidence
peaks around the 7th decade (from the age of 60), and about
20% of patients are aged >80 years. The disease is the 4thmost
common cancer in males and the 15th in females [1]. Bladder
cancer treatment is on a course to becoming an enormous
challenge in the context of an increasingly ageing population.
Overall, the fastest growing population segment is that
aged 80 years or older, which has increased from 13.8 million
in 1950 to 69.2 million in 2000; it is expected to further rise to
379.0 million by 2050 [2]. Due to increased life expectancy and
improved diagnostic techniques, cancers are more frequently
diagnosed, resulting in higher incidence and prevalence rates.
Consequently, more elderly patients will require cancer
treatment.
Evidence-based guidelines recommend radical cystectomy
(RC) for patients with stage II muscle-invasive bladder cancer
(MIBC). However, according to the Surveillance, Epidemiology,va, April 2015.
icle under the CC BY-NC-ND license (http://creativecommons.org/
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 02and End Results database, only 21% of 3262 patients over the
age of 65 underwent RC [3]. Older age at diagnosis and higher
comorbidity were associated with decreased odds of receiving
cystectomy, even if overall survival (OS) was better for those
who underwent cystectomy compared with those who
received alternative treatments (chemotherapy and/or radia-
tion) [3]. Similarly, according to the U.S. National Cancer Data
Base, out of 28,691 patients with clinical T2eT4a, N0e3 MIBC,
no potentially curative therapy was delivered to 47.5% of pa-
tients. Use of RC declined dramatically with advancing age [4].
Thus, guideline-recommended RC is underused for patients
with MIBC, particularly in elderly patients. The reasons that
make bladder cancer unresectable or inoperable are either
related to the tumour itself or to the patient. First, extensive
local tumours (stage T4) might be technically inoperable; the
option of shrinking the tumour with chemotherapy may be
considered. Second, inoperabilitymay be due to patient age or
comorbidities (renal function impairment, cardiovascular
disease, etc.). Other potential factors defining cystectomy
candidates include functional (physical) status, adequacy of
social support and psychological state, nutritional status,
cognitive status, economic and environmental status [5].
In the context of the overall ageing population and the
expected increase in incidence of invasive cancer in patients
above the age of 65 years [6], comorbidities in elderly pa-
tients associated with prognostic implications must be taken
into account by treating physicians. In uro-oncology, age-
related physiological changes and comorbidities affect
treatment choices and outcomes. Comorbidities in the
bladder cancer population include renal function impair-
ment, cardiovascular disease, neuropathy and hearing loss.
Cardiovascular disease and chronic kidney disease (CKD) are
more prevalent in the elderly (>65 years) [7e9]. In addition,
10e25% of individuals over the age of 65 are characterised as
frail [10]. Older and ‘unfit’ bladder cancer patients are
frequently underrepresented in clinical trials [11e13].
Importantly, not all individuals over the age of 65 are
‘elderly.’ A distinction between chronological and functional
age must be made. Fit 70-year-olds with adequate renal
function tolerate cisplatin-based chemotherapy as well as
their younger counterparts and achieve comparable clinical
outcomes [14]. Patients should be routinely categorised ac-
cording to their physiological age in order to gauge whether
elderly bladder cancer patients are fit enough to receive
cisplatin, which forms the backbone of standard chemo-
therapeutic treatment.
2.2. Geriatric screening tools
Elderly cancer patients are a heterogeneous group with
respect to overall health status, due to differences in
comorbidities, functional status, geriatric syndromes and so-
cioeconomic aspects. Although it is not standard, the
comprehensive geriatric assessment (CGA) is recommended
for routine use in the older patient population with cancer by
several societies, including the International Society of Geri-
atric Oncology [15,16] and the National Comprehensive Can-
cer Network [17]. The CGA can distinguish fit patients from
vulnerable or frail patients more precisely than physician's
evaluations [18], in order to provide an estimate ofphysiological age and improve anti-cancer treatment. How-
ever, because the CGA is a resource-consuming process that is
not necessary in all patients, several geriatric screening tools
have been developed to identify elderly cancer patients who
would benefit from a CGA and multidisciplinary approach
(reviewed in [15]). With the Flemish version of the Triage Risk
Screening Tool and Vulnerable Elders Survey-13, the G-8
geriatric screening tool is one of the most studied tools, and
has the highest sensitivity [15]. The G-8 total score ranges
from 0e17, with a cut-off value of 14 (14 and above being
favourable, and <14 indicating impairment, which requires
CGA). The vast majority of users (98.7%) complete the test in
less than 10 min (Table 1) [19].
Thus, a treatment algorithm can be derived, based on G-8
screening scores (Fig. 1). ‘Fit’ patients are those with a score of
14 and above and they require no geriatric assessment.
‘Vulnerable’ and ‘frail’ patients are those with a score below
14 and require geriatric assessment. In the case of ‘vulnerable’
patients, geriatric interventions can reverse various comor-
bidities such as abnormal activities of daily living (ADL) grades
I or II, malnutrition, depression, or cumulative illness rating
scale for geriatrics (CISR-G) grades I or II. ‘Frail’ patients are
those for whom geriatric interventions cannot reverse
comorbidities, such as abnormal ADL3, severemalnutrition,
cognitive impairment, CISR-G grades III or IV [19].
In cancer patients as a whole, it is becoming increasingly
clear that treatment should be adapted to health status. On
the one hand, ‘fit’ patients should receive the same standard
treatment as younger patients, corresponding to approxi-
mately 50% of men aged 70e75 years and about 25% of men
aged 80e85 years. ‘Vulnerable’ patients require geriatric
intervention followed by standard treatment. On the other
hand, ‘frail’ patients should receive geriatric intervention
followed by adapted or palliative treatment, and those who
are ‘too sick’ should receive palliative treatment only [20].
2.3. Conclusions
Performing a geriatric approach as part of a collaborative
multidisciplinary effort is simply equivalent to goodmedicine.
It is important to invest time in the care of elderly patients, in
order to ultimately save time, provide better treatment and
quality of life for these patients. Strategies to improve cancer
care in the elderly are urgently needed.3. Limitations of local treatment and
alternative options in invasive bladder tumours
Nicolas Mottet, France
3.1. Local treatment: standard of care
The standard or care in MIBC is neoadjuvant chemotherapy
followed by RC and pelvic lymph node dissection (PLND).
Neoadjuvant chemotherapy is recommended for T2eT4a,
cN0M0 bladder cancer, and should always be cisplatin-based
combination therapy. Neoadjuvant chemotherapy is not rec-
ommended in patients who are ineligible for cisplatin-based
combination chemotherapy. Surgical intervention or multi-
modality treatments are the preferred curative therapeutic
Table 1 e The G-8 questionnaire [19].
Items Possible responses (score)
A Has food intake declined over the past 3 months due to loss of appetite,
digestive problems, chewing, or swallowing difficulties?
0 ¼ severe decrease in food intake
1 ¼moderate decrease in food intake
2 ¼ no decrease in food intake
B Weight loss during the last 3 months? 0 ¼ weight loss >3 kg
1 ¼ does not know
2 ¼ weight loss between 1 and 3 kg
3 ¼ no weight loss
C Mobility? 0 ¼ bed or chair bound
1 ¼ able to get out of bed/chair but does not go out
2 ¼ goes out
E Neuropsychological problems? 0 ¼ severe dementia or depression
1 ¼mild dementia
2 ¼ no psychological problems
F BMI? (weight in kg)/(height in m2) 0 ¼ BMI <19
1 ¼ BMI 19e<21
2 ¼ BMI 21e<23
3 ¼ BMI 23
H Takes more than three prescription drugs per day? 0 ¼ yes
1 ¼ no
P In comparison with other people of the same age, how does the patient
consider his/her health status?
0.0 ¼ not as good
0.5 ¼ does not know
1.0 ¼ as good
2.0 ¼ better
Age 0: >85
1: 80e85
2: <80
Total score 0e17
BMI, body mass index.
Reproduced from Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric
screening tool. Ann Oncol 2012;23:2166e72. With permission from Oxford University Press.
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 0 3approaches, as they are more effective than radiotherapy (RT)
alone. Multimodality treatment could be offered as an alter-
native in selected, well-informed and compliant patients,
especially for whom cystectomy is not an option [21]. Strati-
fying elderly patients according to their riskebenefit profile
using a multidisciplinary approach will help to select patientsFig. 1 e The G-8 geriatric screening tool (based on [19]). ADL, acti
for geriatrics; IADL, instrumental activities of daily living.most likely to benefit from radical surgery and to optimise
treatment outcomes. The decision regarding bladder-sparing
or RC in elderly/geriatric patients with MIBC should be based
on tumour stage and comorbidity best quantified by a vali-
dated score [21] and patient's wishes, and not on the patient's
age.vities of daily living; CISR-G, cumulative illness rating scale
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 043.2. Cystectomy
3.2.1. Undertreatment of MIBC
Evidence-based guidelines recommend RC for patients with
MIBC, butmany patients receive alternative therapies, such as
chemotherapy or radiation. A U.S. National Cancer Database
study found that potentially curative aggressive therapy (i.e.
radical or partial cystectomy or definitive radiation/chemo-
radiotherapy [CRT, total dose 50 Gy]) was only delivered to
52.5% of patients, and use of aggressive therapy significantly
decreased with advancing age (Fig. 2) [4].
Other studies have shown that cystectomy is underused in
senior adults, including analyses stratifying patients by T
stage [22,23]. Further, a study on bladder cancer patterns of
care observed that cystectomy for muscle-invasive disease
was influenced by patient age and geographic region and not
by comorbidities [24].
3.2.2. Survival data
Even though cystectomy is underused in MIBC, it is associated
with better survival, independently of age, socio-economic
status and serious comorbidity [25e27]. Tumour stage and
number of lymph nodes removed have an impact on specific
survival.
Therefore, even if older patients have a higher American
Society of Anesthesiologists score, and receive less adjuvant
treatment, they should not be denied RC if they are deemed fit
to undergo surgery [26,27]. Studies confirm that a considerable
proportion of elderly patients benefit from RC with curative
intent. Of note, postoperative outcomes after RC depend on
surgeon experience and case load [28].3.3. Neoadjuvant chemotherapy
A systematic review and meta-analysis assessed the effect of
neoadjuvant chemotherapy in the treatment of patients with
invasive bladder cancer. Based on 11 trials involving 3005
patients, a significant survival benefit associated with
cisplatin-based combination chemotherapy (hazard ratio
[HR] ¼ 0.86, 95% confidence interval [CI] 0.77e0.95, p ¼ 0.003)
was observed, equivalent to a 5% absolute improvement in
survival at 5 years. However, there was not sufficient evidenceFig. 2 e Distribution of primary therapies received by MIBC pat
© European Association of Urology 2012.to reliably determine the effect of single-agent cisplatin on
survival [29].
A Medical Research Council/European Organisation for
Research and Treatment of Cancer (MRC/EORTC) trial pre-
sented the long-term results (median follow-up 8 years) of the
international multicentre randomised trial that investigated
the use of neoadjuvant cisplatin, methotrexate, and vinblas-
tine (CMV) chemotherapy in patients with MIBC treated by
cystectomy and/or RT (of note, 17% were older than 70 years).
Results showed a statistically significant 16% reduction in the
risk of death (HR, 0.84; 95% CI, 0.72e0.99; p ¼ 0.037, corre-
sponding to an increase in 10-year survival from 30e36%) after
CMV. In MIBC, neoadjuvant chemotherapy followed by
definitive local therapy should be viewed as state of the art,
compared with cystectomy or RT alone [30].
3.4. Adjuvant chemotherapy
The role of postoperative adjuvant cisplatin-based chemo-
therapy compared with control (surgery alone) in the man-
agement of MIBC has been assessed in a meta-analysis
involving 945 patients from nine randomised controlled trials
(RCTs). For OS, the pooled HR across all nine trials was 0.77
(95% CI, 0.59e0.99; p ¼ 0.049) [31].
After stratification of studies by nodal involvement, the HR
for disease-free survival (DFS) associated with adjuvant
cisplatin-based chemotherapy in studies where more than
50% of patients had pNþ was 0.39 (95% CI, 0.28e0.54),
compared with an HR of 0.89 (95% CI, 0.69e1.15) when less
than 50% of patientswere pNþ. Thus, according to this review,
postoperative adjuvant cisplatin-based chemotherapy mainly
benefits patients with nodal involvement. Furthermore adju-
vant chemotherapy will never be able to compensate for poor
surgical procedure, such as omitting the extended lymphnode
dissection (LND) [32].
The EORTC 30994 study compared immediate versus de-
ferred cisplatin-based combination chemotherapy after RC in
patients with pT3epT4 or Nþ M0 UC of the bladder. In total,
284 (out of 660 planned) patients were randomly assigned (141
to immediate treatment and 143 to deferred treatment), and
after a median follow-up of 7 years, 47% of patients in the
immediate treatment group had died compared with 57% in
the deferred treatment group. No significant improvement inients by age group [4]. Reproduced with permission.
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 0 5OS was noted with immediate treatment when compared
with deferred treatment [33]. However, these results are un-
derpowered and still inconclusive, while suggesting a survival
benefit only in node-negative patients. Therefore, no formal
conclusion can be made regarding which patients benefit the
most from adjuvant chemotherapy.
3.5. CRT with transurethral resection of the bladder
Radiotherapy is an alternative to cystectomy inMIBC patients.
Numerous phase I/II studies have shown that CRT with tran-
surethral resection of the bladder (TURB) is feasible and safe.
Three phase III studies have demonstrated a benefit in terms
of local control compared to RT alone: (i) RT versus
RT þ cisplatin [34]; (ii) RT versus RT þ nicotinamide/carbogen
[35]; (iii) RT versus RT þ fluorouracil/mitomycin C [36]. The
latter randomly assigned 360MIBC patients with amedian age
of 72 years. At 2 years, the rates of locoregional DFS were 67%
(95%CI, 59e74) in the CRT group and 54% (95%CI, 46e62) in the
RT group. Five-year OS rates were 48% (95% CI, 40e55) in the
CRT group and 35% (95% CI, 28e43) in the RT group (HR, 0.82;
95% CI, 0.63e1.09; p ¼ 0.16).
A combined analysis of six prospective Radiation Therapy
Oncology Group (RTOG) protocols evaluated bladder-
preserving combined-modality therapy (CMT, all of which
included cisplatin) in 468 MIBC patients (median age 66 years
[range, 34e93 years, 36% were >70 years], clinical T stage
T2eT4a). With a median follow-up of 4.3 years among all pa-
tients and 7.8 years among survivors (n ¼ 205), the 5- and 10-
year OS rates were 57% and 36%, respectively, and the 5- and
10-year disease-specific survival (DSS) rates were 71% and
65%, respectively. This pooled analysis of multicentre, pro-
spective RTOG bladder-preserving CMT protocols suggests
long-term DSS comparable to modern immediate cystectomy
studies, for patients with similarly staged MIBC [37].
Additional reports from multiple institutional and coop-
erative group studies have shown that this approach is safe
and effective, with OS rates similar to RC in well-selected
patients [38,39]. The best cancers eligible for bladder preser-
vation are those with low-volume T2 disease without hydro-
nephrosis or extensive carcinoma in situ [39] and treated
initially with a thorough TURB (as complete as possible). Thus,
concomitant CRT is emerging as an attractive alternative for
bladder preservation in selected MIBC patients, provided, pa-
tients be fit enough to receive the chemotherapy drugs.
In order to address whether cystectomy is better than
external-beam radiotherapy, the survival benefit achieved
with RC was compared with ERBT in patients with MIBC
stratified by age. Those who underwent RC had an OS
advantage in all age groups, except for octogenarians (18
versus 15months). Patients above the age of 80who receive RC
with a limited PLND or RC alone showed little (16 versus 15
months) or no survival benefit. However, DSS was signifi-
cantly higher in patients who underwent RC, including octo-
genarians. Even if this comparison is limited by its
retrospective nature, it once again highlights that RC is
effective, provided it is well done and includes a real lym-
phadenectomy [40].
In the MRC/EORTC trial that presented the long-term re-
sults of CMV chemotherapy in 976 MIBC patients treated bycystectomy and/or RT [30], there was no evidence that neo-
adjuvant CMVwasmore or less effectivewhen combinedwith
either RT or cystectomy. For locoregional DFS, there was some
evidence of a greater impact with CMV over no CMV given
before cystectomy than the same chemotherapy given before
RT. However, this comparison is limited, as the patient groups
cannot be compared due to differences in patient and tumour
characteristics (tumour stage, N0 nodal status, and perfor-
mance status [PS]).
In summary, CRT with TURB results in optimal outcomes,
provided the tumour is a single lesion T2, complete TURB is
performed, there is no hydronephrosis or tumour invasion into
prostate stroma, the patient has a well functioning bladder,
and no carcinoma in situ. A formal efficacy comparison be-
tween this bladder-sparing approach and a RC is still lacking.
3.6. TURB alone
A Spanish study analysed the long-term results of an aggres-
sive TURB for MIBC treatment in patients who were biopsied
in the deepmuscle layer of the tumour bed. A comparison to a
control group of 76 patients with invasive pathological stage
pT2e3a, N0-3 bladder cancer treated with RC was performed.
At 5 and 10 years of follow-up, cause-specific survival rates
were 80.5% and 74.5%, respectively. No significant difference
was noted in terms of cause-specific survival with respect to
the control group. For patients with invasive bladder cancer,
radical TURBmight be an option when the tumour is clinically
limited to the muscular layer and when all biopsies of the
periphery and depth of the tumour bed show muscular tissue
negative for tumour cells [41].
Another study determined the 10-year outcome of MIBC
patients treated with TURB alone. Of 432 patients (tumour
stage T2, N0, M0), 151 had a restaging TUR of the primary
tumour site showing no (T0) or only non-muscle-invasive (T1)
residual tumour. 52 patients opted for immediate RC, while 99
chose a bladder-sparing approach. The 10-year DSS was 76%
of 99 patients who accepted to receive TURB as definitive
therapy (57% with bladder preserved) compared with 71% of
52 patients who had immediate cystectomy (p ¼ 0.3). The
study suggested that radical TURB is a successful bladder-
sparing therapeutic strategy in selected patients who have
no residual tumour on a repeat extended resection of the
primary tumour [42].
3.7. Partial cystectomy
There is very little evidence on partial cystectomy in MIBC
patients. The most recently published study was a retro-
spective analysis that included 101 patients followed-up for a
median of 53 months [43]. Multivariate analysis showed that
prior history of UC was associated with a decrease of both
cancer-specific survival (CSS) and recurrence-free survival
(RFS), and was weakly associated with OS; while lymphovas-
cular invasion (LVI) and ureteral reimplantation were associ-
ated with a decreased OS, CSS, and RFS.
An earlier retrospective study in 58 patients who had un-
dergone partial cystectomy with LND reported an overall 5-
year survival of 69% with a mean follow-up of 33 months. Of
these patients, 74% were alive with an intact bladder, and
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e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 0655% had been continuously disease-free with an intact
bladder. On multivariate analysis, concomitant carcinoma in
situ (odds ratio [OR] 7.05, p ¼ 0.004) and lymph node involve-
ment (OR 4.38, p ¼ 0.031) were predictors of advanced recur-
rence [44]. However, unlike reports by Dandekar et al. and
Malkowicz et al., this study did not comment on lesion local-
isation [45,46].
Recent population-based series and single institution co-
horts have found that partial cystectomy did not compromise
survival when compared to RC in very selected patients with
organ-confined disease, a single limited lesion without carci-
noma in situ, N0, and mainly located at the bladder dome.
Additional research is needed to clarify patient selection and
outcomes [47].
3.8. Palliative radiotherapy: hypofractionation
Reasons for being unfit and for qualifying to receive palliative
treatment alone include age, comorbidity, palliation of
symptoms, and short life expectancy. In these situations,
palliation is the priority. Hypofractionation might represent
an attractive modality, avoiding too many journeys to the
radiotherapy department and the associated fatigue (Table 2).
3.9. Conclusions
The standard treatment approach in MIBC is neoadjuvant
chemotherapy followed by RC and PLND. Age is not a limita-
tion for optimal treatment, whereas comorbidity and indi-
vidual life expectancy are. There are effective alternative
treatments in the form of bladder-sparing strategies, of partial
surgery (super selection) and combined CRT (with or without
cisplatin). Finally, palliative RT is proposed to very unfit
patients.4. Challenging patient profiles and ‘unfit’
patients in advanced UC
Maria De Santis, United Kingdom
4.1. Standard chemotherapy
The standard of care for advanced and metastatic UC is
cisplatin-based combination chemotherapy. Long-term OS
and progression-free survival (PFS) after treatment with
gemcitabine plus cisplatin (GC) or methotrexate/vinblastine/
doxorubicin/cisplatin (MVAC) have been shown to be similar,
as were response rates. Only toxicity was in favour of GC
[52,53] (Table 3).
Cisplatin has also been compared with carboplatin in
cisplatin-eligible UC patients (Table 4). The carboplatin com-
binations of all trials resulted in lower complete response (CR)
rates and shorter OS. A comparative effectiveness study of 286
patients from four randomised trials confirmed that cisplatin-
based chemotherapy was associated with a significantly
higher likelihood of achieving a CR (risk ratio [RR] ¼ 3.54; 95%
confidence interval [CI] 1.48e8.49, p ¼ 0.005) and overall
response rate (ORR) (RR ¼ 1.34; 95% CI 1.04e1.71, p ¼ 0.02) [55].
Thus, the standard first-line chemotherapy for UC should be
cisplatin-based, which provides 13e15 months of OS.
Table 3 e Long-term follow-up data of cisplatin
combination chemotherapy.
Author
Treatment
arm
N (ITT) Median
follow-up
(years)
Median
survival
(months)
5-year
(%)
Sternberg,
2006 [54]
263 7.3 14.9
MVAC 129 15.1 13.5
HD-MVAC 134 21.8
von der Maase,
2005 [53]
405 >5
MVAC 203 14.0 15.3
GC 202 15.2 13.0
Visceral
metastases
6.8
No visceral
metastases
21.9
GC, gemcitabine plus cisplatin; HD, high dose intensity; ITT,
intention to treat; MVAC, methotrexate, vinblastine, doxorubicin,
and cisplatin.
Table 5 e First-line chemotherapy in advanced/
metastatic UC in routine practice.
Community
database [59]
N ¼ 298
RISC group
[60] N ¼ 1077
No chemotherapy 24% 30%
Cisplatin-based 36% 36%
Carboplatin-based 27% 20%
Non-platinum regimen 8% 14% (1 agent: 11%)
Data non-available 5% e
RISC, Retrospective International Study of Invasive/Advanced
Cancer of the Urothelium; UC, urothelial carcinoma.
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of 298 patients presenting with advanced UC to 42 community
cancer centres were treated with cisplatin [59]. This percent-
age was similar for 1077 ‘real world’ patients treated in 23
centres of excellence [60] (Table 5). A more recent published
study on patterns of practice in 327 advanced UC patients in
Greece reported that 55% did not receive cisplatin-based
therapy [61]. Given that the majority of patients may not be
eligible to receive cisplatin-based chemotherapy, this popu-
lation has a significant unmet need.
4.2. ‘Unfit’ for cisplatin
There is so far no established standard chemotherapy in pa-
tients who are ‘unfit’ to receive cisplatin, even though more
than 50% of UC patients are not eligible for standard cisplatin-
based chemotherapy [20,62e64]. As discussed, comorbidities
and age mean that elderly patients are often excluded or
under-represented in clinical trials. It is, therefore, not clear
whether dosages investigated in clinical trials are realistic or
safe in the elderly and comorbid population.
In the first randomised phase III trial for cisplatin-ineligible
patients conducted by the EORTC, patients were defined asTable 4 e Randomised phase II studies of cisplatin versus
carboplatin in cisplatin-eligible UC patients.
Regimens CR (%) OS (months) Reference
MVAC versus MVECa 25
11
13
9.5
Petrioli,
1996 [56]
MVAC versus Carbo/MV 13 16 Bellmunt,
1997 [57]0 9
GC versus Carbo/gem 14.5 12.8 Dogliotti,
2007 [58]1.8 9.8
Carbo/gem, carboplatin, gemcitabine; Carbo/MV, carboplatin,
methotrexate, vinblastine; CR, complete response; GC, gemcitabine
plus cisplatin; MVAC, methotrexate, vinblastine, doxorubicin, and
cisplatin; MVECa, methotrexate, vinblastine, epirubicin and car-
boplatin; OS, overall survival; UC, urothelial carcinoma.unfit to receive cisplatin if their creatinine clearance (CrCl)
was <60ml/min and/or the ECOG PSwas 2 [62,65,66]. In 2011, a
consensus conference provided amore uniform description of
patients unfit for cisplatin for inclusion in clinical trials [65]
(Table 6).
Performance status in patients unfit to receive cisplatin
must be taken into account with functional status, or with
other assessment tools (e.g. CGA). Since no standard chemo-
therapy has been established for this patient group, the
development of well tolerated single-agent therapy or
cisplatin-free combination regimens is a priority in view of the
substantial number of patients who are not eligible for
cisplatin.
4.3. Treatment of bladder cancer in the elderly
The main challenge when treating bladder cancer in the
elderly is the use of cisplatin, whose pharmacokinetic prop-
erties principally rely on renal elimination [67]. With
increasing age, comorbidities increase and renal function
decreases [68]. Therefore, serum creatinine will be cleared
more slowly in older patients, andwill not provide an accurate
reflection of renal function. Renal dysfunction is common in
oncology patients and many chemotherapy agents, including
cisplatin, are nephrotoxic. Renal function should be evaluated
before every treatment course in all cancer patients, using
either the Cockcroft-Gault or the Modification of the Diet in
Renal Disease (MDRD) formulae, including in patients with
normal serum creatinine. The use of additional nephrotoxic
agents should be avoidedwhenever possible. Reduced or split-Table 6 e Eligibility criteria for enrolling metastatic UC
patients ‘unfit’ for cisplatin-based chemotherapy in
clinical trials [65].
Eligibility criteria (at least one of the following)
1. WHO or ECOG PS 2 or Karnofsky PS of 6070%
2. CrCl (calculated or measured) <60 ml/min
3. CTCAE v4 grade II audiometric hearing loss
4. CTCAE v4 grade II peripheral neuropathy
5. NYHA class III heart failure
CrCl, creatinine clearance; CTCAE, Common Terminology Criteria
for Adverse Events; ECOG, Eastern Cooperative Oncology Group;
NYHA, New York Heart Association; PS, performance status; WHO,
World Health Organization; UC, urothelial carcinoma.
Reproduced with permission. © 2011 American Society of Clinical
Oncology. All rights reserved.
Table 7 e Outcomes of patients who refused cystectomy
after receiving neoadjuvant chemotherapy for MIBC.
Herr, 2008
[71]
Sternberg,
2003 [72]
Meyer,
2014 [73]
CR after neoadjuvant
MVAC (cT0)
N ¼ 63 N ¼ 37 N ¼ 25
5-year survival DSS 64% 68% 88%
Intact bladder 54% 51% 72%
Relapse in bladder 64% 35% 52%
Muscle invasive 28%
Non-muscle invasive 24%
Relapse metastatic NR 24% e
Additional mortality 30% 32% e
Alive with bladder
intact
NR 38% e
CR, complete response; DSS, disease-specific survival; MVAC,
methotrexate, vinblastine, doxorubicin, and cisplatin; NR, not re-
ported; MIBC, muscle-invasive bladder cancer.
Table 9e EORTC 30986 study: first-line therapy in bladder
cancer patients unfit for cisplatin-based chemotherapy
[78].
Regimen ORR (%)
confirmed
(%)
OS
(months)
Severe acute
toxicity (%)
Toxic
death (%)
GCa 41.2
36.1
9.3 9.3 1.7
M-CAVI 30.3
21.0
8.1 21.2 3.4
GCa, gemcitabine/carboplatin; M-CAVI, methotrexate, carboplatin,
and vinblastine; ORR, overall response rate; OS, overall survival.
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 08dose cisplatin, or reduced infusion rates, should be adminis-
tered to avoid excessive toxicity in elderly patients. It is also
important to monitor hydration. Moreover, patients above 70
years of age are frequently diagnosed with CKD and have
more prevalent comorbidities (hypertension, diabetes, stroke
and ischaemic heart disease) than patients without CKD [69].
In addition, the occurrence of neuropathy is associated
with cumulative doses of cisplatin and taxanes. Age is also a
risk factor for developing peripheral neuropathies induced by
chemotherapy [70].4.4. Bladder preservation after chemotherapy
According to the European Association of Urology guidelines,
chemotherapy alone is not recommended for the treatment of
the primary tumour [21]. The main reason is the high inci-
dence of relapse in the bladder, with added mortality. The
outcomes of patients who did not undergo cystectomy after
having received neoadjuvant chemotherapy for MIBC are
summarised in Table 7. Clinically complete responders
after neoadjuvant chemotherapy for MIBC may have the op-
tion to retain the bladder with durable survival, but the added
risks and deviation from the guidelines must be openly
discussed.Table 8 e Selected first-line treatment studies in unfit patients
Author, year Phase, N Patient profile
Doxorubicinegemcitabine/ paclitaxelecarboplatin
Galsky, 2007 [83] II; 25 CrCl <60 ml/min and/or prior
Bevacizumab þ gemcitabineecarboplatin/ bevacizumab
Balar, 2013 [84] II; 51 CrCl <60 ml/min and/or solita
kidney and/or KPS 60e70%
Gemcitabine
Culine, 2011 [82] R II; 21 CrCl 30e60 ml/min and/or PS
Sunitinib
Bellmunt, 2011 [85] II; 38 CrCl 30e60 ml/min (PS 0e1)
KPS, Karnofsky performance status; PFS, progression-free survival; ORR,
NR, not reported; UC, urothelial carcinoma.4.5. First-line treatments in unfit patients
Various combination regimens in patients unfit for cisplatin-
based chemotherapy show an ORR of at best 30e40% and a
median OS of 8e10 months [74e82]. Single arm studies with
more positively selected patients, in particular those having a
solitary kidney as single inclusion criterion for cisplatin inel-
igibility, reported longer OS with up to 15 months (Table 8)
[82e85].
The EORTC 30986 study is the only available phase III trial
that compared two carboplatin-containing first-line chemo-
therapy regimens (methotrexate, carboplatin, and vinblastine
[M-CAVI] versus gemcitabine/carboplatin [GCa]) in clearly
defined cisplatin-ineligible patients with advanced UC [78]
(Table 9).
No significant differences in OS and PFSwere observed, but
a significant difference for confirmed RR was noted in favour
of GCa (36.1% versus 21%, p ¼ 0.01) (Table 9). Fewer adverse
events (AEs) were reportedwith GCa, but therewere still grade
III/IV AEs (neutropenia 52.5%; thrombocytopenia 48.3%; febrile
neutropenia [FN] 4.2%). In patients with both PS 2 and
impaired renal function, increased severe acute toxicities
(SAT, defined as death, grade IV thrombocytopenia with
bleeding, grade III/IV renal toxicity, FN or mucositis), low
response rate and a shorter OS were reported. This led to the
recommendation against combination chemotherapy in such
patients and in favour of single-agent therapy or best sup-
portive care (BSC). The EORTC 30986 study also reported low
efficacy and elevated SAT in patients negatively selected ac-
cording to known prognostic factors [78,86]..
ORR (%) Median PFS
(months)
Median OS
(months)
nephrectomy 56 NR 15
ry 43 6.5 13.9
2 43 3.8 5.4
8 4.8 8.1
overall response rate; CrCl, creatinine clearance; OS, overall survival;
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vinflunine first-line treatment in cisplatin-unfit patients are
ongoing. Vinflunine is a novel anti-cancer agent approved for
advanced or metastatic UC previously treated with a
platinum-based regimen. The Northern Urology Cooperative
Oncology Group 1 trial is comparing vinflunine plus gemci-
tabine versus GCa. The JASINT open-label, multicentre, in-
ternational randomised phase II study is assessing the
combination of gemcitabine or carboplatin with vinflunine
[87]. Preliminary safety results showed more haematological
grade III/IV AEs in the carboplatin arm [87]. Clinical out-
comes, response rates and survival are expected to be pub-
lished soon.
4.6. Second-line treatment options
Choice of second-line therapy depends on time to progres-
sion after first-line treatment, renal function, and PS [21].
Several traditional cytotoxic agents as well as novel targeted
agents have been tested in the second-line setting. Response
rates of taxanes (weekly paclitaxel, docetaxel, nab-
paclitaxel), oxaliplatin, ifosfamide, topotecan, pemetrexed,
lapatinib, gefitinib and bortezomib have been modest (up to
28%) in small phase II trials [88,89]. Gemcitabine has shown
very good response rates, but most patients already receive
this drug during first-line treatment [90]. Paclitaxel/gemci-
tabine studies have shown response rates of up to 60%, but
randomised phase III trials evaluating this combination in
the second-line setting have not included an adequate
comparator arm [91e93].
Several single-agent phase II studies have tested targeted
therapies in the second-line setting, but none have shown
substantial activity. Trials are also testing targeted agents
combined with a cytotoxic drug (paclitaxel þ cetuximab or
docetaxel þ vandetanib), but the combinations exacerbated
toxicity, and no synergistic or additive effects were reported
[94,95]. More recent attempts at combining targeted agents
with cytotoxic drugs have been more encouraging
(docetaxel þ ramucirumab versus docetaxel), based on the
results of a phase II trial, although toxicity was increased in
the combination arm [96]. Another single-arm phase II study
which combined pazopanibwith paclitaxel reported good ORR
values but significant myelosuppression [97].
A phase III trial compared long-term OS of patients with
advanced UC treated with vinflunine plus BSC or BSC alone,Table 10 e Vinflunine efficacy in routine practice.
Germany [101] France [101]
Patients 77 134 38
1st-line therapy Platinum-based chemotherapy
ECOG PS/Karnofsky Median Karnofsky: 80 PS 0: 25%
PS 1: 46%
PS 2: 23%
PS
PS
Visceral involvement 60% (visceral) 57% (lung þ liver) 39
Number of cycles Average: 5 Median: 5 (1e23) M
ORR (%) 23 22 32
DCR (%) 53 51 53
DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group; Oafter failure of platinum-based chemotherapy [98]. The study
showed a >2 month survival difference in favour of the vin-
flunine arm, which was maintained after >3.5 years' follow-
up. With vinflunine, the risk of death was reduced by 22%.
There were also some long-term survivors in the vinflunine
arm (at 40 months follow-up cut off) [98]. For second-line
treatment of advanced or metastatic UC, this trial reached
the highest level of evidence ever reported. Currently, vin-
flunine is the only approved second-line treatment [21].
Adverse prognostic factors validated in vinflunine studies
for pretreated patients include liver metastases, Hb <10 g/dl,
and ECOG PS 1 [99,100]. Available prospective and retro-
spective data on vinflunine use in routine practice for
unselected populations include 422 patients from 87 centres
(Table 10).
These recent data from European phase IV studies per-
formed in real life confirm the efficacy of vinflunine, even in
patients with adverse prognostic factors [101]. Each of these
studies report a median OS that exceeds the 6.9 months re-
ported in the phase III trial [98]. In real life, vinflunine was safe
with manageable toxicity (Table 11). Myelosuppression is
usually managed with granulocyte colony-stimulating
factor in these patients, particularly if dose modifications
are insufficient [105].
Vinflunine is especially interesting in the context of special
patient populations, including those with renal or hepatic
impairment, and elderly patients. Vinflunine has been shown
to be safe in patients with a CrCl as low as 20 ml/min [106].
These conditions are not contraindications to vinflunine use,
but require dose adjustments. In the case of renal impairment,
the dose needs adjusting according to CrCl values. In patients
whose CrCl is 60 ml/min, standard vinflunine dosing of
320 mg/m2 every 3 weeks (q3w) is recommended, or 280 mg/
m2 q3w in patients who are PS 1 or who have received prior
radiotherapy. The same lower dose of 280 mg/m2 q3w is rec-
ommended in patients whose CrCl is 40e60 ml/min, and a
further reduced dose of 250mg/m2 q3w in patients whose CrCl
is 20e40 ml/min. The large experience in the post-platinum
setting, phase II and III study data, and real world experi-
ence all demonstrate that vinflunine is safe in patients with
CrCl <60ml/min. Indeed, the ‘tolerance profile of vinflunine in
patients with renal dysfunction was similar to that observed
in patients with CrCl >60 ml/min’ [106]. Vinflunine can be
used in patients with hepatic impairment, provided it is not
severe. Doses of 250 mg/m2 or 200 mg/m2 q3w areUK [102] Spain [103] Greece [104]
102 71
0e1: 92%
2: 8%
PS 0: 31%
PS 1: 61%
PS 2: 8%
PS 0: 24%
PS 1: 53%
PS 2: 20%
PS 3: 3%
% (lung) 29% (liver) 29% (lung) 17% (liver) 42% (lung) 30% (liver)
edian: 3 (1e16) Median: 4 (1e18) Median: 4 (1e16)
25 16.3
66 e
RR, overall response rate; PS, performance status.
Table 11 e Vinflunine safety in routine practice.
Grade III/IV adverse events Germany
(n ¼ 77) [101]
France
(n ¼ 134) [101]
UK
(n ¼ 38) [102]
Spain
(n ¼ 102) [103]
Greece
(n ¼ 71) [104]
Haematological adverse events (% patients)
Neutropenic infection or febrile neutropenia (%) 1 3 5 NR NR
Neutropenia (%) NR 17 3 13 16.3
Anaemia (%) 6 8 5 NR 4.1
Non-haematological adverse events (% patients)
Constipation (%) 5 8 11 6 12.2
Abdominal pain (%) NR 3 0 5 NR
Asthenia/fatigue (%) 1 21 8 NR 16.3
Vomiting (%) 3 NR 0 2 NR
NR, not reported.
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 010recommended in patients with mild Child-Pugh Grade A and
moderate (Grade B) impairment, respectively.
In addition, vinflunine is safe in elderly patients; most
common AEs do not differ from those seen in younger pa-
tients. Similarly to patients with renal impairment, based on
pharmacokinetic and safety data, vinflunine should be
started at 280 mg/m2 q3w in patients who are aged 75e79
years, and the dose should be lowered to 250 mg/m2 q3w in
patients aged 80 years who are in good shape [107]. The
decision on which dose to administer depends on biological
parameters. Upper age thresholds are currently not outlined
in clinical trials.
4.7. Conclusions
Urothelial cancer patients are of higher median age and often
present with organ impairment and comorbidities. Cisplatin-
based chemotherapy is the standard first-line treatment in
advanced UC. However, more than 50% of patients are not
eligible for cisplatin due to age and/or renal comorbidities,
meaning that alternative treatment options are needed for
these patients. Medical management should consider neph-
rotoxicity of drugs and patients' performance status and organ
function.
The first randomised phase II/III trial in ‘unfit’ patients
showed that M-CAVI and GCa are active, with a toxicity profile
in favour of GCa. Thus, in patients ineligible for cisplatin due
to a single risk factor (e.g. renal function), the standard
regimen is GCa. There may be a role for splitting cisplatin
doses in the case of renal function impairment. Patients
ineligible for cisplatin are not a uniform group, and successful
outcomes of combination therapy depend on renal function,
PS and the presence/absence of prognostic factors. In frail
patients, recommended treatment options include carbopla-
tin or gemcitabine monotherapy, or GCa if possible. This
population is challenging because these patients are difficult
to include and accrue in clinical trials.
Novel treatments and combinations with vinflunine are
promising in an area of unmet need in the first-line setting in
patients who are elderly or unfit to receive cisplatin. Vin-
flunine has a favourable toxicity profile, including in elderly
patients or in patients with impaired renal function, provided
that the dose is adjusted. For second-line treatment of
advanced or metastatic UC, vinflunine is currently the only
approved treatment option, although many trials haveevaluated traditional cytotoxic agents and combinations with
targeted agents.5. Management of upper tract UC: surgical
aspects
Nicolas Mottet, France
5.1. Surgery
The standard surgical modality in UC of the upper urinary
tract (UTUC) is a radical nephroureterectomy (RNU) plus
LND followed by single immediate postoperative intravesical
instillation (usually withmitomycin C). New data suggest that
a systematic conservative approach is standard of care in
selected patients (Fig. 3) [108].
Low-risk UTUC is defined by the presence of all the
following factors: unifocal disease, tumour size <1 cm, low-
grade cytology, low-grade ureteroscopic (URS) biopsy, and no
invasive aspect on multidetector computed tomography-
urography. On the other hand, high-risk UTUC is defined by
the presence of either of these factors: hydronephrosis,
tumour size >1 cm, high-grade cytology, high-grade URS bi-
opsy, multifocal disease, and previous RC for bladder cancer
[108].
In case of lesion suspicion upon imaging and negative or
low-grade cytology, it is recommended to perform an ure-
teroscopy and biopsy, whereas ureteroscopy is optional in the
case of positive cytology.
5.1.1. Conservative treatment (low-risk UTUC)
Techniques used in the conservative management of low-risk
UTUC are as follows [108]:
 Laser should be used for endoscopic treatment
 Flexible ureteroscopy is preferable to rigid ureteroscopy:
especially for renal pelvis, distal, and mid-ureter
 A percutaneous approach remains an option in low-grade
tumours unsuitable for URS treatment
Conservative treatment may also be extended to (low-
grade only) multifocal lesions (pelvis only) without ureteral
locations or tumours <3 cm, provided they are in the pelvis
and non-flat. In the future, biological markers associated with
low-grade lesions may play a role in patient selection. One
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 0 11unsolved issue is the role of adjuvant (mainly percutaneous)
instillations in low-risk UTUC patients.
5.1.2. Lower ureter management
Conservative treatment is performed most of the time in the
distal ureter, provided the approach is feasible. Endoscopic
removal is recommended in low-grade, small, non-circular
tumours. Complete distal ureterectomy and neocystostomy
are indicated for non-invasive, low-grade tumours in the
distal ureter that cannot be removed completely endoscopi-
cally, and for high-grade, locally-invasive (i.e. T2) tumours. Of
note, the upper ureter must be normal, and kidneys must be
functional [108].
5.1.3. Radical surgery (high-risk UTUC)
RNU plus LND is recommended in high-risk UTUC patients.
The procedure involves removal of perinephretic fat. No dif-
ference in recurrence or cancer-specific mortality has been
reported when comparing open versus laparoscopic RNU in
1249 patients from 13 international centres [109], provided
that surgical principles are respected and that the urinary
tract is closed.
It is essential to remove the bladder cuff in RNU. The
prognostic impact of bladder cuff excision at nephroureter-
ectomy on cancer-specific mortality was quantified in a
population-based cohort of 4210 UTUC patients. In univariable
and multivariable analyses, omission of bladder cuff excision
increased cancer-specific mortality rates in patients with
pT3N0/x, pT4N0/x, and pT(any)N1e3 UC of the renal pelvisFig. 3 e Proposed flowchart for the management of UTUC [108].
conservative approach. CT, computed tomography; RNU, radica
cell carcinoma.[110]. Unfortunately, in real practice the standard principle of
RNU with systematic bladder cuff removal is not followed in
about 50% of patients despite clear guidelines [109].
Intravesical recurrence after RNU is a frequent event
requiring intense bladder surveillance with endoscopy. A
retrospective analysis in 2681 patients treated with RNU for
UTUC at 24 international institutions compared outcomes
following RNU using three different methods of bladder
cuff management (transvesical, extravesical, and endo-
scopic) [111]. Of the 2681 patients, 67.5% underwent the
transvesical approach; 29.3%, the extravesical approach;
and 3.2%, the endoscopic approach. There was no difference
in terms of RFS, CSS, and OS among the three distal ureteral
management approaches. Patients who underwent the
endoscopic approach were at significantly higher risk of
intravesical recurrence compared with those who under-
went the transvesical (p ¼ 0.02) or extravesical approaches
(p ¼ 0.02); the latter two groups did not differ from each
other [111].
5.1.4. Nodal dissection
Nodal dissection is not necessary if pTa/1: max 2% pNþ, but it
is mandatory in the following instances: pT2 (16% pNþ); pT2
(8% pNþ); pT3 (17% pNþ), or pT4 (46% pNþ). RNU provides
local control and CSS in patients with localised UTUC. Path-
ologic tumour grade, T stage, LN status, tumour architecture,
and LVI are important prognostic variables associated with
oncologic outcomes, which could potentially be used to select
patients for adjuvant systemic therapy [112].*In patients with solitary kidney, consider a more
l nephroureterectomy; UTUC, upper urinary tract urothelial
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templates remain to be established to perform the procedure.
This depends on lesion location and requires formal clinical
validation [108] (Table 12).
5.1.5. Postoperative instillation
Guidelines for RNU in UTUC recommend postoperative
instillation following surgery to avoid bladder recurrence
[108]. Two studies have demonstrated that a single immediate
postoperative bladder instillation dose reduces the risk of
bladder tumour recurrence [113,114].
5.2. Conclusions
The main take home message in terms of UTUC surgical
management is that a conservative procedure should be
applied when feasible. Patients are required to have a closed
urinary tract. If RNU is performed, it must include bladder cuff
removal and early postoperative instillation at urethral cath-
eter removal; nodal dissection must also be carried out in
muscle-invasive lesions.6. Molecular specificities in UC
Joaquim Bellmunt, Spain
6.1. Introduction
New options are needed for treating metastatic bladder can-
cer, since median survival and response rates with standard
therapy (MVAC) have evolved little over the last 30 years. As
discussed, superficial disease is treated with TURB plus
intravesicular therapy, which includes Bacillus Calm-
etteeGuerin (BCG), mitomycin C, or other investigational
agents such as gemcitabine. Localised muscle-invasive dis-
ease is managed with cystectomy and neoadjuvant (the
standard) or adjuvant chemotherapy; chemoradiation is used
if a bladder-sparing approach is opted for. Metastatic disease
is treated mainly with chemotherapy, and there are a wide
variety of available agents whose role is well established,
including cisplatin, carboplatin, or gemcitabine. Immuno-
therapy and targeted therapies are emerging and highly
promising strategies that are awaiting confirmation for being
established in this setting.
An improved understanding of molecular specificities of
bladder cancer will provide new opportunities for prognosticTable 12 e Lesion location and nodal dissection.
Lesion location Location of nodal dissection
Right pyelic lesion Renal hilum, para, retro cave
Left pyelic lesion Renal hilum, para-aortic
Right lumbar ureter
(down to iliac vessels)
Renal hilum, para,
retro cave, inter-aorticocave
Left lumbar ureter
(down to iliac vessels)
Renal hilum, para-aortic
Right ureter (below
iliac vessels)
Primitive external, internal
obturator
Left ureter (below
iliac vessels)
Primitive external, internal
obturatorapplication and personalised therapy. The sections below
present an overview of the latest cancer genomics data in UC,
and the potential use of tumour genetics in bladder cancer.
In the future, precision medicine and the analysis of large-
scale somatic and germline genomics may impact individual
patient treatment in bladder cancer and individualise patient
care.
6.2. Recurrence and progression in high-grade
‘superficial’ bladder cancer
Approximately 21% of superficial bladder cancers progress to
muscle-invasive or more advanced disease stages, and 50% of
localised muscle-invasive disease progresses to metastatic
disease. Although risk tables provide a prognostic tool, no
molecular biomarkers accurately predict disease recurrence,
progression or cancer-specific mortality [115].
A recent meta-analysis in high-grade T1 non-muscle-
invasive bladder cancer assessed selection criteria for early
cystectomy in these patients. The highest impact risk factor
was depth of invasion (T1b/c) into lamina propria (progres-
sion: HR ¼ 3.34, p < 0001; CSS: HR ¼ 2.02, p ¼ 0.001). Several
other factors also predicted progression and CSS (LVI, asso-
ciated clinically-isolated syndrome, non-use of BCG, tumour
size >3 cm, and older age) [116].
6.3. Chemotherapy in muscle-invasive disease
As discussed, the timing of perioperative chemotherapy in
MIBC patients is a subject of debate. Benefit of neoadjuvant
chemotherapy is now well established, but survival benefit
from adjuvant chemotherapy seems less evidence-based. An
updated meta-analysis on the benefit of postoperative adju-
vant cisplatin-based chemotherapy versus surgery alone in
945 patients from nine RCTs reported the following efficacy
outcomes, providing evidence of a survival benefit in MIBC
patients receiving adjuvant cisplatin-based chemotherapy
after RC [31] (Table 13).
Larger studies of adjuvant chemotherapy from meta-
analyses and retrospective cohorts show some OS benefit,
but not with a high level of evidence (Table 14).
6.4. Molecular determinants of response
Several genetic UCmolecularmarkers that predict response to
chemotherapy are emerging. Whole exome sequencing onTable 13 e Efficacy of postoperative adjuvant cisplatin-
based chemotherapy versus surgery alone in MIBC
patients receiving adjuvant cisplatin-based
chemotherapy after RC [31].
End-point HR 95% CI p Value
OS 0.77 0.59e0.99 0.049
OS in LN (þ) 0.66 0.45e0.91 0.014
DFS 0.66 0.48e0.92 0.014
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio;
LN, lymph node; MIBC, muscle-invasive bladder cancer; OS, overall
survival; RC, radical cystectomy.
Table 14 e Efficacy of adjuvant chemotherapy from meta-analyses and retrospective cohorts.
Reference Design Total N (adjuvant
chemo. n)
Level of
evidence
OS HR (95% CI)
ABC, 2005 [117] Individual patient data meta-analysis from 6 RCTs 491 (246) 2a 0.75 (0.60e0.96)
Leow, 2014 [31] Literature-based meta-analysis from 9 RCTs 945 (475) 2a 0.77 (0.59e0.99)
Svatek, 2010 [118] Retrospective cohort study from 11 high
volume centres
3947 (932) 2c 0.85 (0.72e0.97)*
Booth, 2014 Population-based retrospective cohort 2809 (541) 2c 0.71 (0.62e0.81)
Galsky, 2015 Population-based retrospective cohort 5653 (1293) 2c 0.72 (0.65e0.80)
Cancer-specific survival. CI, confidence interval; HR, hazard ratio; OS, overall survival; RCT, randomised controlled trial.
e j c s u p p l em en t s 1 4 ( 2 0 1 6 ) 1e2 0 13pretreatment tumour and germline DNA from 50 patients
with MIBC who received neoadjuvant cisplatin-based
chemotherapy followed by cystectomy identified ERCC2, a
nucleotide excision repair gene, as being mutated in cisplatin
responders compared with non-responders [119].
Similarly, a pathologic CR to neoadjuvant chemotherapy
containing platinum is a strong prognostic determinant for
MIBC patients. Erb-b2 receptor tyrosine kinase 2 (ERBB2) mu-
tations characterise a subgroup of MIBC with excellent
response to neoadjuvant therapy [120].
A neoadjuvant clinical trial is underway to compare the
clinical efficacy of GC versus MVAC and the ability of a gene
expression profiling-based algorithm (CoXEN) to predict
complete pathological response [121].Table 15 e Planned interim analysis grade ≥III AEs safety
results [96].
Docetaxel
(N ¼ 44)
Docetaxel þ
ramucirumab
(N ¼ 46)
Haematological toxicities
Neutropenia 36 28
Febrile neutropenia 11 20
Anaemia 5 9
Thrombocytopenia 0 76.5. Bladder-preservation as a CMT
Long-term outcomes in MIBC patients after bladder-
preserving CMT were assessed in a pooled analysis of five
phase II studies and one phase III study that included a total of
468 patients. With a median follow-up of 7.8 years among
survivors (n ¼ 205), the 5- and 10-year OS rates were 57% and
36%, respectively, and the 5- and 10-year DSS rates were 71%
and 65%, respectively. The study demonstrated long-term
outcomes comparable to modern immediate cystectomy
studies. Given these long-term outcomes, bladder-preserving
CMT can be considered as an alternative to RC, especially in
elderly patients not well suited for surgery [37].
Protein expression of DNA damage signalling proteins in
tumour samples was measured prior to radical radiotherapy
or cystectomy in MIBC patients. In the RT cohort, low tumour
MRE11 expression was associated with worse 3-year CSS
compared with high expression, highlighting this protein as a
predictive factor associated with survival following RT [122].
A report in patients with clinical stage T2e4a MIBC treated
with TURB plus cisplatin-based induction and consolidation
chemoradiation regimens (and RC for invasive tumour
recurrence) showed variations in 3-year OS estimates
depending on vascular endothelial growth factor (VEGF)
expression patterns [123].Non-haematological toxicities
Fatigue 11 33
Pneumonia 9 13
Sepsis 7 9
Stomatitis 0 7
Diarrhoea 2 7
AEs, adverse events.6.6. Precision oncology
The progression towards targeted therapy in UC is underway.
Some cancers are still treated with non-specific or non-
targeted chemotherapy. ‘Druggable’ tumour-specific genetic
targets are increasingly the focus of research. In other cancers,molecular profiling has identified single drug targets such as
BCR-ABL in chronic myeloid leukaemia, KRAS in colorectal
cancer, or BRAF in melanoma.
So far, no molecularly targeted agents have been approved
for bladder cancer treatment. Genomic alterations of
anaplastic lymphoma kinase (ALK) have been reported in UC
patients, but no association between ALK copy number alter-
ation andOS, ECOG PS, or development of visceral diseasewas
observed [124].
Bladder cancer is a molecularly heterogeneous disease.
The Cancer Genome Atlas (TCGA) project reported molecular
alterations in several genes involved in cell cycle regulation,
chromatin regulation, and kinase signalling pathways, iden-
tifying potential therapeutic targets [125]. The TCGA findings
have prompted the design of several genomic target driven
trials.
6.6.1. Cell cycle regulatory genes, signalling pathways and
immunotherapy
An ongoing phase II trial is testing palbociclib (PD-0332991) in
patients with metastatic UC with mutated RB and inactivated
p16 or overexpressed CCND1 after failure of first-line
chemotherapy. The trial will explore the association of mo-
lecular markers with outcomes of palbociclib response and
the association between UC molecular subtypes (basal-like or
luminal) with outcomes of response or resistance to palboci-
clib (ClinicalTrials.gov Identifier: NCT02334527).
Whole-genome sequencing was used to investigate the
genetic basis of a durable remission of metastatic bladder
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hibits the mammalian target of rapamycin (mTOR) signalling
pathway. A loss-of-function mutation was identified in tu-
berous sclerosis complex 1 (TSC1), a regulator of mTOR
pathway activation. TSC1 mutation correlated with ever-
olimus sensitivity [126]. As a result, several ongoing phase I/II
trials are investigating the impact of PI3K/mTOR pathway
genomic alterations in metastatic UC patients treated with
various regimens, in order to help identify the best responding
patients. In addition, fibroblast growth factor receptor (FGFR)
tyrosine kinase inhibitors are an emerging area of interest in
cancer therapeutics. Proof-of-concept was recently estab-
lished by two trials targeting FGFR3 in previously-treated
FGFR3-mutant or translocated metastatic UC [127,128].
Studies are being designed in order to accelerate clinical
drug development in UC. The Alliance MATCH-UP study aims
to apply molecular findings to clinical trials by allocating
drugs based on molecular screening in metastatic UC
following platinum-based chemotherapy.
Finally, the programmed death-1 (PD-1) receptor/PD-1
ligand (PD-L1) pathway negatively regulates T-cell-mediated
responses. The prognostic impact of PD-L1 expression was
defined in UC. Results from 160 tumour samples showed that
PD-L1 is widely expressed in tumour cell membrane and
tumour-infiltrating mononuclear cells (TIMCs). PD-L1
expression in TIMCs was significantly associated with longer
survival in patients who developed metastases [129] and
received subsequent chemotherapy. Using PD1 or PD-L1 as a
target, several studies have shown encouraging results with
anti-PD-L1 antibodies (pembrolizumab andMPDL3280A) in UC
patients with PD-L1-positive advanced tumours [130,131].
Promising long lasting responses have been seen in a selected
subgroup of patients. These drugs are now undergoing testing
in phase III trials versus chemotherapy, in the second-line
setting.6.7. Intrinsic subtypes in MIBC
In other diseases such as breast cancer, intrinsic subtypes are
well characterised (e.g. luminal, HER2-positive, triple-
negative) [132], each of which are associated with distinct
clinical management approaches. The objective in UC has
been to develop similar treatment algorithms. Based on cur-
rent research, the following intrinsic subtypes and clinical
features have been described in MIBC [133,134]:
 Luminal: enriched with papillary histology and activating
FGFR3 mutations and translocations. About half of the tu-
mours are sensitive to neoadjuvant chemotherapy. Ther-
apies include GC/dose-dense MVAC, and possibly FGFR
inhibitors.
 p53-like: infiltrated with stromal fibroblasts, bone metas-
tases. Resistant to neoadjuvant chemotherapy. Therapies
may include Met-inhibitors or initial surgery.
 Basal: enriched with squamous features, immature signa-
ture, angiogenesis. More common in women. Associated
with advanced stage, metastatic disease at presentation,
shorter DSS and OS in the absence of chemotherapy. About
half of the tumours are sensitive to neoadjuvantchemotherapy. Therapies include GC/dose-dense MVAC
and possibly CTLA4/PD1/PDL-1, or VEGF inhibitors.
 Claudin-low/mesenchymal: clinical features are not well
defined. Probably enriched with sarcomatoid features and
associated with high metastatic potential.
6.8. Conclusions
An increasing number of studies are bridging the gap between
translational science and novel biomarker-driven clinical tri-
als, establishing molecular-based therapies for bladder can-
cer. For instance, expression analysis of DNA damage
signalling proteins in tumour samples taken before irradiation
could be used as a predictive marker of RT response and may
ultimately allow patient selection for RT or cystectomy, thus
improving overall cure rates.
Studies have demonstrated the feasibility of using whole-
genome sequencing in the clinical setting to identify bio-
markers of drug sensitivity that can aid in the identification of
patients most likely to respond to targeted anti-cancer
therapies.
Bladder cancer can no longer be thought of as a single
disease; subtyping should be considered, and may have im-
plications on selecting therapy. Application of biomarkers is
set to fundamentally change bladder cancer treatment.
7. Perspectives for the future of UC
Joaquim Bellmunt, Spain
7.1. First-line therapies
As mentioned earlier, the advances achieved in the last 30
years of randomised trials evaluating systemic chemotherapy
in the treatment of advanced bladder cancer are limited.
Advanced bladder cancer seems to have reached a plateau
with regard to median survival of patients, averaging
approximately 15 months.
The standard chemotherapy regimens in 2015 for the first-
line treatment or ‘fit’ patients are GC or MVAC or a regimen
combining paclitaxel and GC in selected patients. GC and
MVAC have level 1 evidence and grade A recommendation
[21,135].
In ‘unfit’ patients, the combination of carboplatin and
gemcitabine is now considered the best option based on a
randomised phase II/III trial conducted in the EORTC (EORTC
30986) versus the previously used regimen M-CAVI [78].
Knowing that vinflunine is an effective drug with a safe
profile in patients with impaired renal function, the open-
label, multicentre, international JASINT-1 randomised phase
II study assessed the combination of gemcitabine or carbo-
platin with vinflunine [87]. The initial promising data from
JASINT-1 is being further evaluated in the JASINT-2 rando-
mised phase III study comparing vinflunineegemcitabine
versus gemcitabineecarboplatin doublet combinations in 162
patients unfit for cisplatin with advanced or metastatic UC.
7.2. Second-line therapies
The most promising single-agent second-line chemotherapy
is vinflunine, a third-generation semi-synthetic vinca
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bination chemotherapy for metastatic disease, vinflunine
should be offered; alternatively, due to the limitations in this
setting, treatment within a clinical trial may be offered (grade
A* recommendation) [21]. Currently, vinflunine is the only
approved second-line drug and the only drug that has proven
beneficial both within a phase III study and in real world data
[98,101e103]. A long list of single-agent second-line chemo-
therapy trials is available for advanced bladder cancer
(reviewed in [89]).
Vinflunine’smechanismof action is threefold, in that it is a
microtubule inhibitor with anti-angiogenic activity that re-
verses epithelial-to-mesenchymal transition [136,137]. More-
over, it has anti-angiogenic activity at non-cytotoxic
concentrations and can inhibit metastasis and impact on
epithelial-to-mesenchymal transition at low doses (in vitro
studies) [138e140].
7.3. Second-line targeted therapies
Many single-agent phase II studies with targeted therapies
have been tested in the second-line setting, but no substantial
activity has been demonstrated as single agents. These
include gefitinib, bortezomib, lapatinib, sorafenib, sunitinib,
aflibercept, pazopanib, volasertib, everolimus, vandetanib,
temsirolimus, and dovitinib.
Furthermore, targeted agents combined with a cytotoxic
drug (paclitaxel þ cetuximab or docetaxel þ vandetanib) in
platinum-pretreated patients did not demonstrate additive
activity and resulted in increased toxicities [94,95].
The VEGF pathway may play an important role in the
pathogenesis of bladder cancer. Previous phase II trials failed
to demonstrate activity as single agents, but more recent
phase II combination studies have led to more promising re-
sults. Ramucirumab, a human VEGFR2-targeted monoclonal
antibody, has demonstrated clinical activity in several solid
tumours with preclinical testing supporting a role for ramu-
cirumab/taxane combinations in UC. In an ongoing phase II
study in the second-line setting of advanced or metastatic
UC, patients were randomised equally to one of three open-
label treatments: docetaxel (n ¼ 44); docetaxel and ramucir-
umab (n ¼ 46); or docetaxel and icrucumab (n ¼ 49). Ran-
domisation was stratified by the absence/presence of
visceral metastases and receipt of prior anti-angiogenic ther-
apies [96]. While docetaxel þ icrucumab led to minimal ac-
tivity (ORR 10%, disease control rate [DCR] 31%) and
development of icrucumab was interrupted in bladder cancer,
the ORR for docetaxelþ ramucirumabwas 19.6 versus 4.5% for
docetaxel (p ¼ 0.0502) and the DCR was 67.4 versus 43.2%
(p ¼ 0.033). Median interim PFS data were also significantly in
favour of docetaxel þ ramucirumab versus docetaxel: 22
weeks versus 10.4 weeks (p < 0.001), providing a basis for
testing ramucirumab in a phase III study now enrolling 524
patients (docetaxel þ ramucirumab versus docetaxel þ
placebo). Nevertheless, toxicities were increased in the
docetaxel þ ramucirumab arm with a high rate of FN (20%
versus 11%with docetaxel only) (Table 15). Themost common
grade III AEs from the interim analysis are summarised
(Table 15) [96].Another recent single-arm phase II study combined an
angiogenesis inhibitor (pazopanib) with weekly paclitaxel in
32 pretreated patients with refractory urothelial cancer [97].
Objective responses were observed in 50% of patients,
with PFS and OS values of 6 and 8 months, respectively.
Seventy-five percent of patients required dose reduction
and 44% of patients received growth factors. Despite the
impressive ORR value, OS is similar to many other trials,
and myelosuppression was significant. The initially
planned phase III study was cancelled based on a corporate
decision.
7.4. Maintenance therapy
Maintenance therapy has an established role in some diseases
such as advanced non-small cell lung cancer, in which pa-
tients receive continuation maintenance therapy or switch to
another agent (e.g. pemetrexed or erlotinib) based on the
benefits observed in randomised trials [141e143]. The key
objectives of maintenance therapy are to delay progressive
disease and increase OS. Secondary objectives include the
prevention of symptom deterioration and maintenance of PS
to allow further therapy.
Which role and which UC patients would best benefit
from such a treatment approach remains to be established.
Maintenance therapy in UC was investigated with the re-
ceptor tyrosine kinase inhibitor sunitinib versus placebo after
first-line chemotherapy in a randomised phase II, double-
blind study. From 54 randomised patients, the median PFS
was 2.9 months with sunitinib versus 2.7 months with pla-
cebo. Similarly, no difference in OS was reported (10.5
months with sunitinib versus 10.3 months with placebo). The
study was limited by premature closure and a small sample
size. Maintenance sunitinib was considered unlikely to
confer benefit in this setting [144]. A second biomarker-
driven trial with maintenance lapatinib in bladder cancer
was presented at ASCO 2015. Despite selecting patients based
on her1 and her2 status, the trial was unable to demonstrate
any benefit [145].
Some additional ongoing trials are investigating the role of
maintenance therapy in advanced UC after first-line chemo-
therapy. Phase II data in fit patients are expected from two
trials. The JASIMA single arm trial is investigating vinflunine
up to disease progression after first-line chemotherapy with
up to four cycles of GC treatment. Responding patients with at
least stable disease were included in the trial. The Spanish
MAJA trial is a randomised multicentre study in which up to
six cycles of primary treatment with GC were allowed. Fit
patients with advanced or metastatic UC not progressing on
palliative first-line cisplatin-based chemotherapy were rand-
omised to receive vinflunine maintenance þ BSC versus BSC
alone. The first preliminary results from the MAJA study pre-
sented at ASCO 2015 (66 patients) indicated that maintenance
vinflunine post-cisplatin has an acceptable tolerability profile
in advanced UC patients. With a median follow-up of 7.2
months, the median PFS was increased by as much as 6
months (10.4 months in the vinflunine arm and 4.6 months in
the BSC arm [p ¼ 0.058]), suggesting that more mature data
may lead to significant PFS differences between arms [146].
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Molecular understanding of bladder cancer biology has lagged
behind other solid cancers, which has represented a major
barrier in improving clinical care. To date, vinflunine is the
only therapy that has been established and has been approved
by the EuropeanMedicines Agency for bladder cancer patients
who recur or are refractory to platinum-based therapy. Data
on vinflunine in first-line ‘unfit’ bladder cancer patients are
highly promising and may be confirmed in the ongoing
JASINT-2 phase III study. The role of maintenance vinflunine
is under study.
Novel targeted therapies in adequately selected, geneti-
cally profiled patients might lead to improvement in thera-
peutic outcomes.
The new emerging immunotherapeutic approach using
check-point inhibitors opens a bright future for a selected
subgroup of advanced bladder cancer patients.Conflict of interest statement
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